MedTrace Logo

The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients

NCT00459940 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2007-04-13

No results posted yet for this study

Summary

In the present double blind, placebo-controlled, parallel study we evaluated the impact of 12 weeks thiazolidinedione (TZD) administration on basal and insulin-stimulated substrate metabolism in growth hormone-replaced adults with growth hormone deficiency.

Conditions

  • Growth Hormone Deficiency

Interventions

DRUG

Pioglitazone

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Jens OL Jorgensen, MD · University of Aarhus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
71 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Completion
2006-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00459940 on ClinicalTrials.gov